CSL Delivers Solid First Half as Seqirus Ramps Up Influenza Vaccine Production
Narrow-moat CSL surprised on the upside with a solid first-half fiscal 2018 result that was buoyed by several positive drivers across the portfolio. These included the better-than-expected success of recent product launches in specialty products and haemophilia, the impact of expanded indications in the core immunoglobulin product offering, and an impressive contribution from sales of seasonal flu vaccines. Despite cycling against a strong prior comparable period, CSL delivered a healthy uplift ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.